Steve Weitman
- Pharmaceutical Science top 1%
- Advanced Drug Delivery Systems 3
- Molecular Medicine top 2%
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery 3
- Oncology top 5%
- Cancer Treatment and Pharmacology 8
- Cancer-related Molecular Pathways 3
- Drug Transport and Resistance Mechanisms 3
- Molecular Biology top 10%
- Cancer therapeutics and mechanisms 9
-
- Chronic Lymphocytic Leukemia Research 7
-
- Acute Lymphoblastic Leukemia research 4
- Co-authors
- Peter L. BonateDaniel D. Von HoffCory L. GrandHaiyong HanRubén M. MuñozLaurence H. HurleyDavid J. BearssMichael Morgan
- Journals
- Clinical Cancer Research (3 papers)Journal of Pediatric Hematology/Oncology (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Steve Weitman
36 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 132
- Pharmaceutical Science 362
- Molecular Medicine 238
- Biomaterials 322
- Oncology 538
- Molecular Biology 1.2k
Countries citing papers authored by Steve Weitman
This map shows the geographic impact of Steve Weitman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Weitman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Weitman more than expected).
Fields of papers citing papers by Steve Weitman
This network shows the impact of papers produced by Steve Weitman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Weitman. The network helps show where Steve Weitman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Steve Weitman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 23 | |
| 2 | 2018 | 66 | |
| 3 | 2013 | 15 | |
| 4 | 2013 | 11 | |
| 5 | 2009 | 6 | |
| 6 | 2007 | 92 | |
| 7 | 2006 | 211 | |
| 8 | 2005 | 2 | |
| 9 | 2005 | 3 | |
| 10 | 2004 | 215 | |
| 11 | 2004 | 35 | |
| 12 | 2004 | 4 | |
| 13 | 2004 | 11 | |
| 14 | 2003 | 21 | |
| 15 | 2002 | 34 | |
| 16 | 2002 | 80 | |
| 17 | 2001 | 474 | |
| 18 | 2001 | 25 | |
| 19 | A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. | 2001 | 98 |
| 20 | Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts. | 1999 | 21 |
About Steve Weitman
Steve Weitman is a scholar working on Genetics, Oncology, Toxicology, Pharmaceutical Science and Transplantation, having authored 36 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (9 papers), Cancer Treatment and Pharmacology (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (4 papers), Nanoparticle-Based Drug Delivery (3 papers), Cancer-related Molecular Pathways (3 papers), Advanced Drug Delivery Systems (3 papers) and Drug Transport and Resistance Mechanisms (3 papers). The work is most often cited by research in Pharmaceutical Science (362 citations), Molecular Medicine (238 citations), Biomaterials (322 citations), Oncology (538 citations) and Molecular Biology (1.2k citations). Steve Weitman has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Peter L. Bonate, Daniel D. Von Hoff, Cory L. Grand, Haiyong Han, Rubén M. Muñoz, Laurence H. Hurley, David J. Bearss, Michael Morgan, Ramesh Rathi and Zina Moldoveanu. Their work appears in journals such as Clinical Cancer Research, Journal of Pediatric Hematology/Oncology, Cancer Chemotherapy and Pharmacology, Journal of Clinical Oncology and International Journal of Gynecological Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.